Christoph Brackmann net worth and biography

Christoph Brackmann Biography and Net Worth

CFO of NovoCure

Christoph Brackmann has served as Novocure’s Chief Financial Officer since January 2025. He oversees the company’s global financial operations, including financial reporting, financial planning and analysis, treasury, tax, and investor relations. Mr. Brackmann joined Novocure in October 2024 as a Senior Financial Advisor.

Before joining Novocure, Mr. Brackmann was Senior Vice President of Finance at Moderna since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. Previous to this role, Mr. Brackmann served as the Vice President of Investor Relations and Head of International Finance at Shire plc (acquired by Takeda), and held various financial roles at Eli Lilly and Company, and Novartis.

Mr. Brackmann earned his Master of Business Administration from the SDA Bocconi School of Management, Milan and holds a bachelor’s degree in Business and Economics from the University of Mannheim.

What is Christoph Brackmann's net worth?: The estimated net worth of Christoph Brackmann is at least $2.16 million as of March 4th, 2026. Brackmann owns 182,842 shares of NovoCure stock worth more than $2,159,364 as of March 22nd. This net worth estimate does not reflect any other investments that Brackmann may own. Learn More about Christoph Brackmann's net worth.
How do I contact Christoph Brackmann?: The corporate mailing address for Brackmann and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Christoph Brackmann's contact information.
Has Christoph Brackmann been buying or selling shares of NovoCure?: In the last ninety days, Christoph Brackmann has sold $85,343.72 in NovoCure stock. Most recently, Christoph Brackmann sold 6,412 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a transaction totalling $85,343.72. Following the completion of the sale, the chief financial officer now directly owns 182,842 shares of the company's stock, valued at $2,433,627.02. Learn More on Christoph Brackmann's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Christoph Brackmann (CFO), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Pritesh Shah (Insider), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, NovoCure insiders bought shares 2 times. They purchased a total of 101,550 shares worth more than $1,228,341.00. During the last twelve months, insiders at the medical equipment provider sold shares 7 times. They sold a total of 140,041 shares worth more than $1,860,116.16. The most recent insider tranaction occured on March, 5th when COO Mukund Paravasthu sold 43,246 shares worth more than $595,497.42. Insiders at NovoCure own 5.5% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 3/5/2026.

Christoph Brackmann Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/4/2026	Sell	6,412	$13.31	$85,343.72	182,842
7/29/2025	Buy	20,000	$11.59	$231,800.00	141,150

Christoph Brackmann Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $11.81

$11.46

$12.14

50 Day Range

MA: $12.46

$10.03

$14.99

2 Week Range

Now: $11.81

$9.82

$20.06

Volume

1,653,032 shs

Average Volume

2,046,208 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71